Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1998-05-18
1999-09-14
Tsang, Cecilia J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 21, 514921, 530324, 530350, 530351, 530830, 424 851, 424 852, 424529, 424534, A61K 3800, A61K 4505
Patent
active
059523026
ABSTRACT:
Disclosed are methods for treatment of humans exposed to bacterial endotoxin in circulation by administration of bactericidal/permeability-increasing (BPI) protein products. Serologically and hematologically verifiable alleviation of endotoxin mediated increases in circulating cytokines, fibrinolysis and coagulation factors and changes in lymphocyte counts are observed upon such treatment. Also observed is alleviation of endotoxin mediated decreases in systemic vascular resistance index (SVRI) and concomitant increases in cardiac index (CI).
REFERENCES:
patent: 5089274 (1992-02-01), Marra et al.
patent: 5171739 (1992-12-01), Scott
patent: 5198541 (1993-03-01), Elsbach et al.
patent: 5234912 (1993-08-01), Marra et al.
patent: 5308834 (1994-05-01), Scott et al.
patent: 5334584 (1994-08-01), Scott et al.
patent: 5348942 (1994-09-01), Little, II et al.
patent: 5643875 (1997-07-01), Friedmann et al.
patent: 5753620 (1998-05-01), Friedmann et al.
Ammons et al., "Recombinant Amino Terminal Fragment of Bactericidal/Permeability Increasing Protein Prevents Hemodynamic Responses to Endotoxin", Circulatory Shock, 41:176-184 (1993).
Baggiolini et al., "Neutrophil-activating Peptide-1/Interleukin 8, a Novel Cytokine That Activates Neutrophils", J. Clin. Invest., 84:1045-1049 (Oct., 1989).
Berry, "Cellular Biology of Endotoxin, Introduction" Handbook of Endotoxin, vol. 3, pp. xvii-xxi, (1985).
Bloom et al., "Serum Neopterin Levels Following Intravenous Endotoxin Adminstration to Normal Humans", Immunobiol., 181:317-323 (1990).
Bone et al., "Definitions for sepsis and organ failure", Critical Care Medicine, 20(6):724-726 (1992).
Bradley et al., "Hemodynamic Alterations in Normotensive and Hypertensive Subjects During the Pyrogenic Reaction", J. Clin. Invest., 24:749-758 (1945).
Brigham et al., "Endotoxin and Lung Injury", Rev. Respir. Dis., 133:913-927 (1986).
Boujoukos et al., "Compartmentalization of the acute cytokine response in humans after intravenous endotoxin administration", J. Appl. Physiol., 74:3027-3033 (1993).
Boujoukos et al., "Detection of Interleukin-8 in Bronchoalveolar Lavage Without Alveolar Neutrophil Influx, Before and After Intravenous Endotoxin in Normal Humans", Am. Rev. Resp. Dis., 145(4):A441 (Apr., 1992).
Calandra et al., "Prognostic Values of Tumor Necrosis Factor/Cachectin, Interleukin-1, Interferon-.alpha., and Interferon-.mu. in the Serum of Patients with Septic Shock", J. Infectious Diseases, 161:982-987 (1990).
Calandra et al., "High Circulating Levels of Interleukin-6 in Patients with Septic Shock: Evolution During Sepsis, Prognostic Value, and Interplay with Other Cytokines", Am. J. Medicine, 91:23-29 (Jul. 1991).
Canon et al., "Circulating Interleukin 1 and Tumor Necrosis Factor in Septic Shock and Experimental Endotoxin Fever", J. Infection Diseases, 161:79-84 (1990).
Cochrane, "The Enhancement of Inflammatory Injury", Am. Rev. Respir. Dis., 136:1-2 (1980).
Colman, "Surface-mediated Defense Reactions, The Plasma Contact Activation System", J. Clin. Invest., 73:1249-1253 (May 1984).
Danner et al., "Endotoxemia in Human Septic Shock", Chest, 99:169-175 (Jan. 1991).
DeLa Cadena et al., "Activation of the Kallikrein-Xn System After Endotoxin Administration to Normal Human Volunteers", Blood, 81(12):3313-3317 (Jun. 15, 1993).
Dinatello, "The Proinflamatory Cytokines Interleukin-1 and Tumor Necrosis Factor and Treatment of the Septic Shock Syndrome", J. Infection Diseases, 163:1177-1184 (1991).
Elin et al., "Effect of Induced Fever on Serum Iron and Ferritin Concentrations in Man", Blood, 49(1):147-153 (Jan. 1977).
Elsbach et al., "Separation and Purification of a Potent Bactericidal/Permeability Increasing Protein and A Closely Associated Phospholipase A2 from Rabbit Polymorphonuclear Leukocytes", J. Biol. Chem., 254:11000 (1979).
Elsbach et al., "Oxygen-Independent Antimicrobial Systems of Phagocytes" Inflammation: Basic Principles and Clinical Correlates, Chapter 30, pp. 603-636, 2nd. Ed., (1990).
Fong et al., "Endotoxemia Elicits Increased Cuiculating B2-IFN/IL-6 in Man", J. Immunology, 142(7):2321-2324 (Apr. 1, 1989).
Fong et al., "The Acute Splanchnic and Peripheral Tissue Metabolic Response to Endotoxin in Humans", J. Clin. Invest., 85:1896-1904 (1990).
Fong et al., "Total Parental Nutrition and Bowel Rest Modify the Metabolic Response to Endotoxin in Humans", Ann. Surg., 210:449-457 (1989).
Gazzano-Santoro et al., "High-Affinity Binding of the Bactericidal/Permeability-Increasing Protein and a Recombinant Amino-Terminal Fragment to the Lipid A Region of Lipopolysaccharide", Infect. Immun. 60(11):4754-4761 (Nov. 1992).
Granowitz et al., "Production of interleukin-1-receptor antagonist during experimental endotoxaemia", Lancet, 338:1423-24 (1991).
Granowitz et al., "Hematologic and Immunomoedulatory Effects of an Interleukin-1 Receptor Antagonist Contusion During Low-Dose Endotoxemia in Healthy Humans", Blood, 82(10):2985-2990 (1993).
Gray et al., "Cloning of the cDNA of a Human Neutrophil Bactericical Protein", J. Biol. Chem., 264(16):9505-9509 (Jun. 5, 1989).
Hack et al., "A Modified Competitive Inhibition Radioimmunoassay for the Detection of C3a", J. Immunol. Meth., 108:77-84 (1988).
Hesse et al., "Cytokine Appearance in Human Endotoxemia and Primate Bacteremia", Surg., Gyn. & Obstet., 166:147-153 (Feb. 1988).
In't Veld., "Effects of the Bactericidal//Permeability-Increasing Protein of Polymorphonuclear Leukocytes on Isolated Bacterial Cytoplasmic Membrane Vesicles", Infect. Immun., 56(5):1203-1208 (1988).
Kelly et al., "Role of the bactericidal permeability-increasing protein in the treatment if gram-negative pneumonia", Surgery, 114(2):140-146 (Aug. 1993).
Kindt et al, "Initial recruitment of neutrophils to alveolar structures in acute lung injury", J. Appl. Physiol., 70:1575-1585 (1991).
Kohn et al., "Protective Effect of a Recombinant Amino-Terminal Fragment of Bactericidal Permeability-Increasing Protein in Experimental Endotoxemia", J. Infect. Diseases, 166:1307-1310 (Nov. 1993).
Kung et al., International Conference on Endotoxemia IV, Amsterdam, The Netherlands, p. 23, Abstr. P3 (Aug. 17-29, 1993).
Leach et al., "Prevention of Lethal Endotoxemia by BP.sub.23 ", J. Cell. Chem, (Keystone Symposia, Suppl. 16(C):172:Abstr. CB 412, (Feb. 21-Mar. 7, 1992).
Levy et al., "Antibacterial 15-kDa Protein Isoforms (p15s) Are Members of a Novel Family of Leukocyte Proteins", J. Biol. Chem., 268:6058-6063 (1993).
MacIntyre et al., "E5 Antibody Improves Outcome from Multi-Organ Failure in Survivors of Gram-Negative Sepsis", Critical Care Medicine, S14 (Apr. 1991).
Mannion et al., "Separation of Sublethal and Lethal Effects of Polymorphonuclear Leukocytes on Escheria coli", J. Clin. Invest., 86:631-641 (Aug. 1990).
Marra et al., "The Role of Bactericidal/Permeability-increasing Protein as a Natural Inhibitor of Bacterial Endotoxin", J. Immunol., 148(2):532-537 (Jan. 15, 1992).
Marra et al., "Bactericidal/Permeability-Increasing Protein Has Endotoxin-Neutralizing Activity", J. Immunol, 144(2):662-666 (Jan. 15, 1990).
Martich et al., "Intravenous Endotoxin Administration to Normal Humans Primes Neutrophils for an Enhanced Respiratory Burst", Critical Care Medicine, 5100 (Apr. 1992).
Martich et al., "Detection of Interleukin 8 and Tumor Necrosis Factor in Normal Humans after Intravenous Endotoxin: The Effect of Antiinflammatory Agents", J. Exp. Medicine, 173:1021-1024 (Apr. 1991).
Martich et al., "Effects of ibuprofen and pentoxifylline on the cardiovascular response of normal humans to endotoxin", J. Appl. Physiol., 73:925-931m (1992).
Martich et al., "Response of Man to Endotoxin", Immunobiol., 187:403-416 (Apr., 1993).
Michie et al., "Detection of Circulating Tumor Necrosis Factor After Endotoxin Administration", N. Eng. J. Medicine, 318(23):1481-1486 (Jun. 9, 1988).
Moore et al., "A Single Dose of Endotoxin Activates Neutrophils without Activating Complement", Surgery, 102:200-205 (Feb. 12-14, 1987).
Moser et al., "Cardiopulmonary Consequences of Pyrogen-Induced Hyperpyrexia in Man", J. Clin. Invest., 42(5):626-634 (1963).
Natanson et al., "Role of Endotoxemi
Friedmann Nadav
Scannon Patrick J.
van Deventer Sander J.H.
von der Mohlen Marijke A.M.
Wedel Nancy
Mohamed Abdel A.
Tsang Cecilia J.
Xoma Corporation
LandOfFree
Human therapeutic uses of BPI protein products does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Human therapeutic uses of BPI protein products, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human therapeutic uses of BPI protein products will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1509764